Cargando…
Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
BACKGROUND: Circulating tumor DNA (ctDNA) has made a breakthrough as an early biomarker in operable early‐stage cancer patients. However, the function of ctDNA combined with cell‐free DNA (cfDNA) as a predictor in advanced non‐small cell lung cancer (NSCLC) remains unknown. Here, we explored its pot...
Autores principales: | Zheng, Jie, Wang, Yubo, Hu, Chen, Zhu, Mengxiao, Ii, Jianghua, Lin, Caiyu, Lu, Conghua, Dou, Yuanyao, Zhao, Chenlong, Zhang, Yimin, Wu, Di, Li, Li, Tang, Huan, He, Tingting, Pan, Chunxiao, Han, Rui, He, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663669/ https://www.ncbi.nlm.nih.gov/pubmed/36193794 http://dx.doi.org/10.1111/1759-7714.14668 |
Ejemplares similares
-
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023) -
Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples
por: Nesic, Marijana, et al.
Publicado: (2021) -
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023) -
The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021) -
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)